Search

There is no standard of care for unresectable cutaneous squamous cell carcinoma (cSCC). Chemotherapy, alone or combined with radiotherapy, is commonly used mostly as palliative treatment; moreover, its poor safety profile limits its use most of the time, especially in elderly patients. Thus, alternative options are needed. Targeted molecular inhibitors, such as the epidermal growth factor receptor inhibitor cetuximab, seem promising, but data are limited. We retrospectively evaluated clinical outcomes of cetuximab as a single agent in this indication. The primary endpoint was the Disease Control Rate (DCR) at 6 weeks according to RECIST criteria. Secondary endpoints included DCR at 12 weeks, objective response rate (ORR) at 6 and 12 weeks, progression-free-survival (PFS), overall survival (OS), and safety profile. Fifty-eight patients received cetuximab as monotherapy. The median age was 83.2 (range, 47.4 to 96.1). The majority of patients was chemotherapy naïve. The median follow-up was 11.7 months (95% CI: 9.6-30.1). The DCR at 6 and 12 weeks was 87% and 70%, respectively. The ORR was 53% and 42%, respectively, at 6 and 12 weeks. The median PFS and OS were 9.7 months (95% CI: 4.8-43.4) and 17.5 months (95% CI: 9.4-43.1), respectively. Fifty-one patients (88%) experienced toxicity, and 67 adverse events related to cetuximab occurred. Most of them (84%) were grade 1 to 2. Our study shows that cetuximab is safe and efficient for the treatment of patients, even elderly ones, with advanced cSCC. These results indicate that cetuximab is a promising agent to test in new combinations, especially with immune checkpoint inhibitors such as anti–PD-1 agents.

Resume La tomographie par emission de positons au 18-fluorodesoxyglucose couplee a la tomodensitometrie ( 18 F-FDG TEP-TDM ou TEP-TDM) est devenue incontournable dans certains domaines de l’imagerie oncologique. Elle est parfois realisee, hors standard, au diagnostic ou dans le suivi des sarcomes. Materiels et methodes Nous avons evalue la pratique et l’impact de la TEP-TDM dans la prise en charge quotidienne des sarcomes de l’adulte a partir des dossiers consecutivement presentes en Reunion de concertation pluridisciplinaire « sarcome » pendant 10 mois. Resultats Sur 232 patients, 50 (21 %) avaient eu une TEP-TDM. La sensibilite et la specificite de la TEP-TDM etaient de 94,7 %, et 57,1 %, respectivement. La valeur de la SUV etait tres variable, y compris pour un sous-type histologique ou un grade donne. La TEP-TDM modifiait la strategie therapeutique dans 14 % des cas. Dans les cas ou des localisations extrapulmonaires sont suspectees pour certains sous-types particuliers de sarcomes, la TEP-TDM peut apporter des informations complementaires en raison de sa bonne sensibilite malgre sa faible specificite. Conclusion Compte tenu de la large predominance de la localisation pulmonaire comme site metastatique, un scanner thoracique en coupes fines est suffisant dans la plupart des cas pour le bilan d’extension. L’utilisation de la TEP-TDM dans le bilan des sarcomes de l’adulte doit etre discutee au cas par cas et sa place reste a preciser par des etudes complementaires.

497 Background: Recent reports demonstrate prognostic and predictive impacts of the location of the primary tumor in metastatic colorectal cancer (mCRC). Our retrospective analysis aimed to determine the influence of primary site on metastatic distribution and disease evolution. Methods: From our database all patients (pts) with mCRC (except transverse carcinoma) treated from 1/12/2007 to 1/12/2016 in our institution were collected. Univariate and multivariate analyses were performed to identify predictors of overall survival (OS). Results: A total of 284 pts with available data were analyzed: 83 with Right-sided Colon Cancer (RCC) (29%), 123 with Left-sided Colon Cancer (LCC) (43%) and 78pts with Rectal Cancer (RC) (28%). Hepatic, lung, lymph nodes and peritoneal metastases were respectively found in 63%, 36%, 23% and 20% of the population. The incidence or number of liver metastases were not influenced by sidedness (p = 0.06), LCC presented more bilobar involvement compared to RCC and RC (p = 0.017). Peritoneal carcinomatosis was significantly correlated to colon cancer (p = 0.002), whereas lung metastases were more common in RC (p < 0.001). Patients with RCC more often presented distal lymph node involvement (p = 0.008). RAS mutation status was known for 241pts (80%), of those 110 (37%) were RAS mutated with no significant differences between RCC, LCC and RC (p = 0.4), BRAF mutation (p = 0.007) was more common in RCC. On a multivariable analysis, primary tumor resection (PTR) and complete response after first line therapy were associated with a better OS but only a trend was observed for LCC and RC. Lung, lymph and peritoneal metastasis were associated with worse OS (Table). Conclusions: These results suggests that mCRC had different clinical presentation at diagnosis, the association with molecular features may explain the independent prognostic factor for OS of the sidedness. [Table: see text]

e20035Background: Rd is a treatment option for patients (pts) ineligible for transplant. Lenalidomide (R) pharmacokinetics (PK) has been evaluated in pts under 65 and very few data are available ab...